mFOLFOX6 + HLX04

mFOLFOX6 + HLX04 is a combination chemotherapy regimen used primarily for the treatment of colorectal cancer. The mFOLFOX6 component consists of modified FOLFOX6 (folinic acid/leucovorin, fluorouracil, and oxaliplatin), while HLX04 is a bevacizumab biosimilar developed by Shanghai Henlius Biotech. The mFOLFOX6 regimen typically includes: - Oxaliplatin 85 mg/m² IV infusion over 2 hours - Leucovorin 400 mg/m² IV infusion over 2 hours (concurrent with oxaliplatin) - Fluorouracil 400 mg/m² IV bolus - Fluorouracil 2400 mg/m² IV continuous infusion over 46 hours HLX04 (bevacizumab biosimilar) is an angiogenesis inhibitor that targets vascular endothelial growth factor (VEGF) to prevent formation of new blood vessels that supply tumors. The complete regimen is typically administered every 14 days (2 weeks) for multiple cycles.

Other names

bevacizumab plus FOLFOX-4bevacizumab with FOLFOX-4bevacizumab + oxaliplatin + leucovorin + fluorouracil